Advertisement
(Logo: http://www.newscom.com/cgi-bin/prnh/20080404/LAF521LOGO)
A live audio webcast of management's presentation will be available on theInvestor Relations section of the Company's web site athttp://www.favrille.com. Alternatively, callers may participate in theconference call by dialing (888) 713-4205 or (617) 213-4862, passcode61931952. To pre-register for this call, please go tohttps://www.theconferencingservice.com/prereg/key.process?key=PFYXYBR33.Callers who pre-register will be given a unique PIN to gain immediate accessto the call and bypass the live operator. You may pre-register at any time,including up to and after the call start time. A telephone replay of the callwill also be available for 48 hours. The telephone replay can be accessed bydialing (888) 286-8010 or (617) 801-6888, passcode 61738291.
Advertisement
About Favrille, Inc.
Favrille, Inc. is a biopharmaceutical company focused on the developmentand commercialization of targeted immunotherapies for the treatment of cancerand other diseases of the immune system. The Company's lead product candidate,Specifid(TM) (formerly FavId(R)), is based upon unique genetic informationextracted from a patient's tumor. Specifid is currently under investigation ina Phase 3 registration trial for patients with follicular B-cell non-Hodgkin'slymphoma (NHL) and Phase 2 clinical trials in other B-cell NHL indications.The Company is developing additional applications based on its immunotherapyexpertise and proprietary cost-effective manufacturing technology, including asecond product candidate, FAV-201, for the treatment of cutaneous T-celllymphoma.
SOURCE Favrille, Inc.
